Ikonisys: Hospitex International to Partner With Allianz Value for First Large-Scale Screening Program Dedicated to Urinary Tract Oncology Diagnostics in Italy
February 29 2024 - 12:30AM
Business Wire
Regulatory News:
Ikonisys SA (Euronext Growth Paris: ALIKO), a company
specializing in the early and accurate detection of cancers through
a unique, fully automated solution for medical analysis
laboratories, today announces the collaboration of Hospitex
International with Allianz Value, a company belonging to Allianz
S.p.A. dedicated to both companies’ welfare solutions and home
health services and health prevention, for the deployment of the
first large-scale screening program dedicated to the urinary tract
oncology diagnostics thanks to Hospitex’s urinary kits, in
Italy.
The screening program, which is free of charge for clients
belonging to large communities who already have welfare programs in
place and who will decide to join this new initiative, involves
Hospitex sending the Urine241 kit, the most innovative service
available on the market in this field, to patients' homes.
On average, urinary tract cancers - mostly bladder cancers -
affect nearly 30,000 new people a year in Italy, with most of them
often asymptomatic. At the time of discovery, those people are
already at an advanced stage, with fatal repercussions for them.
This screening program will thus make possible to identify any
neoplasms at an early stage and enable to intervene with therapies
with a lower impact and a very high probability of cure.
Mario Crovetto, CEO of Ikonisys and Alessandro Nosei,
General Manager of Hospitex and responsible for the development of
Hospitex Solutions - Urine24, said: “This is an important
milestone that we have just reached, further demonstrating the
importance of combining our unique expertise, as it would
officially and shortly materialize upon the closing of Ikonisys'
acquisition of Hospitex. The collaboration with Allianz Value in
Italy, the company focusing on welfare services within Allianz
S.p.A., demonstrates their confidence in our technology and will
allow us to address an area of unmet medical need. This
collaboration also opens new opportunities in the field of
prevention, through predictive analytics. Indeed, we intend to
further extend these initiatives towards a large-scale
implementation of screening, to be able to identify those patients
who are currently unaware that they have a disease in progress,
similarly to what has already been successfully completed with the
Pap test and HPV programs and with the faecal occult blood
test”.
About Allianz Value
Allianz Value, a wholly controlled entity of Allianz S.p.A. in
Italy, is active since 2018 in the segment of welfare services for
companies’ employees and members of large communities. Besides the
flexible benefits services, the company offers further services for
health, provided via dedicated medical platforms with a special
focus on primary and secondary prevention.
About Hospitex International
Hospitex International is the world leading company for cytology
standardized monolayer preparations. With CYTOfast it has
re-invented the cytological diagnostics. Hospitex offers a full
range of integrated solutions aimed at streamlining diagnostic
processes in cytology. The global shortage of expertise in
pathology requires tools and technologies that enable diagnostic
safety, efficiency and capacity building. In this area, Hospitex is
recognized as the precision diagnostics player in cytology.
For more information: https://www.hospitex.com/en/
About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris
(France), New Haven (Connecticut, USA) and Milan (Italy)
specialized in the early and accurate detection of cancer. The
company develops, produces and markets the proprietary
Ikoniscope20® and Ikoniscope20max® platforms, fully-automated
solutions designed to deliver accurate and reliable detection and
analysis of rare and very rare cells. Ikonisys has received FDA
clearance for several automated diagnostic applications, which are
also marketed in Europe under CE certification. Through its
breakthrough fluorescence microscopy platform, the company
continues to develop a stream of new tests, including liquid biopsy
tests based on Circulating Tumor Cells (CTC).
For further information, please go to
www.ikonisys-finance.com
Disclaimer
This press release contains forward-looking statements about the
Company's prospects and development. These statements are sometimes
identified by the use of the future tense, the conditional tense
and forward-looking words such as "believe", "aim to", "expect",
"intend", "estimate", "believe", "should", "could", "would" or
"will" or, where appropriate, the negative of these terms or any
other similar variants or expressions. This information is not
historical data and should not be construed as a guarantee that the
facts and data set forth will occur. This information is based on
data, assumptions and estimates considered reasonable by the
Company. It is subject to change or modification due to
uncertainties relating to the economic, financial, competitive and
regulatory environment. This information contains data relating to
the Company's intentions, estimates and objectives concerning, in
particular, the market, strategy, growth, results, financial
situation and cash flow of the Company. The forward-looking
information contained in this press release is made only as of the
date of this press release. The Company does not undertake to
update any forward-looking information contained in this press
release, except as required by applicable law or regulation. The
Company operates in a competitive and rapidly changing environment
and therefore cannot anticipate all of the risks, uncertainties or
other factors that may affect its business, their potential impact
on its business or the extent to which the materialization of any
one risk or combination of risks could cause results to differ
materially from those expressed in any forward-looking information,
it being recalled that none of this forward-looking information
constitutes a guarantee of actual results.
_____________________ 1 Urine24 is a urinary cytological
examination, collected with a dedicated non-toxic fixative,
performed in standardized monolayer (S-LBC), and reported with the
most advanced medical standard "The Paris System 2019". The service
includes the shipment and collection of the collection kit at the
patient's home, and the sending of the report in digital mode.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240228589475/en/
Allianz Value Media & External Relations Allianz
S.p.A. Press.office@allianz.it
Hospitex International Marco Testini Investor Relations
marco.testini@hospitex.com
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Louis-Victor Delouvrier/Aurélie Manavarere
Investor Relations ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94
94
NewCap Nicolas Merigeau Media Relations
ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Historical Stock Chart
From Apr 2024 to May 2024
Ikonisys (EU:ALIKO)
Historical Stock Chart
From May 2023 to May 2024